We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App





Fapon Spotlights Localization-Focused One-Stop IVD Solutions at WHX Labs Dubai 2026

By LabMedica International staff writers
Posted on 11 Feb 2026

At WHX Labs Dubai 2026, Fapon is showcasing its comprehensive one-stop in vitro diagnostics (IVD) solutions, highlighting capabilities that span raw materials, reagent development, and open-system platforms. More...

The company is presenting its technologies February 10–13 at the Dubai World Trade Centre, drawing on more than two decades of experience supporting global IVD manufacturers.

A central focus of Fapon’s presence is its Local Manufacturing Solutions, which support localization across chemiluminescence immunoassay (CLIA), clinical biochemistry, lateral flow assay (LFA), and molecular diagnostics platforms. These solutions provide full-chain technology transfer, covering core raw materials, reagent solutions, open-system instruments, R&D expertise, and production processes, enabling partners to establish end-to-end local manufacturing and commercialization capabilities.

Fapon is also highlighting its blood-based Alzheimer’s disease (AD) testing solution, which supplies bulk reagents and raw materials for key biomarkers including p-tau 217, p-tau 181, Aβ40, Aβ42, GFAP, and NfL. These biomarkers exhibit high sensitivity and specificity and correlate strongly with predicate kits and established clinical diagnostic tests, empowering IVD manufacturers worldwide to develop more accurate and reliable AD assays.

In addition, Fapon is demonstrating its chemiluminescence one-stop solution, including the Shine series CLIA analyzers with throughputs ranging from 120 T/h to 900 T/h, more than 70 self-developed reagent solutions, and supporting core raw materials. The company is also showcasing recombinant quality control and calibrator materials, including RF, HbA1c, and HIV/HIV-P24, as well as LAMP-based solutions for rapid molecular diagnostics.

Supported by manufacturing facilities spanning more than 100,000 m² and a global R&D and production network, Fapon supplies partners in over 70 countries and regions and collaborates with more than 2,500 organizations worldwide.

Related Links:
Fapon Biotech

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
Pre- Eclampsia Control
Acusera Pre-Eclampsia Control
New
MR-proADM Test
B•R•A•H•M•S MR-proADM KRYPTOR test
New
Fully Automated Urinalysis System
DxU 1800 Fully Automated Urinalysis System
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers identified 157 metabolites linked to BBB damage, including 25 that appeared in at least two independent studies (Image Credit: Adobe Stock)

Blood Metabolite Patterns May Enable Early Detection of Blood-Brain Barrier Injury

Early injury to the blood-brain barrier (BBB) can precede many neurological disorders but remains difficult to detect noninvasively. Laboratory markers that identify barrier dysfunction before symptoms... Read more

Molecular Diagnostics

view channel
Image Credit: Shutterstock

Blood Test for Lung Cancer Screening Receives FDA Breakthrough Device Designation

Lung cancer remains the leading cause of cancer death in the United States, yet only about 18% of people eligible for screening undergo low-dose computed tomography, the current guideline-recommended method.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.